5700-53-8

Usage

InChI:InChI=1/C8H18N2/c9-6-7-10-8-4-2-1-3-5-8/h8,10H,1-7,9H2

Upstream product

• 1074-58-4 N-(cyanomethyl)cyclohexylamine 
• 64-17-5 ethanol 
• 108-94-1 cyclohexanone 
• 107-15-3 ethylenediamine 
• 108-93-0 cyclohexanol 

Downstream Products

• 51055-39-1 N-[2-(bis-carboxymethyl-amino)-ethyl]-N-cyclohexyl-glycine 
• 151793-15-6 4-Amino-5-chloro-N-(2-cyclohexylamino-ethyl)-2-methoxy-benzamide 
• 51099-11-7 1-cyclohexyl-2-iminoimidazolidine hydrochloride 
• 76210-60-1 1-(2-Cyclohexylamino-ethylamino)-3-phenoxy-propan-2-ol; hydrochloride 
• 1234260-21-9 (1-cyclohexyl-imidazolidin-2-ylidene)acetonitrile 
• 1329673-99-5 1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclohexylamino)ethylamino)ethanol 
• 1350273-79-8 C₂₂H₃₁N₅O₃ 
• 26075-79-6 1-[4-(2-acetylamino-ethyl)-benzenesulfonyl]-3-cyclohexyl-imidazolidin-2-ylideneamine 
• 25862-65-1 1-<sulfonyl>-3-cyclohexyl-2-iminoimidazolidine dihydrochloride 
• 58493-43-9 N-cyclohexyl-N'-cyclohexyliden-ethylenediamine 
• 5427-42-9 N-(7-chloroquinolin-4-yl)-N'-cyclohexylethane-1,2-diamine 

Relevant academic research and scientific papers

N-alkylation of ethylenediamine with alcohols catalyzed by CuO-NiO/γ-Al2O3

A simple method for N-alkylation of 1, 2-diaminoethane with different alcohols in a fixed-bed reactor using cheap CuO-NiO/γ-Al2O 3 as the catalyst has been developed. The present catalytic system was applicable in the N-alkylation of 1, 2-diaminoethane with both primary and secondary alcohols. Mono-N-alkylation of 1, 2-diaminoethane with low-carbon alcohols resulted in high yields; the yields of tetra-N-alkylation of 1, 2-diaminoethane with low-carbon alcohols declined markedly with the increase of the molecular volume of alcohols.

N-alkylation of ethylenediamine with alcohols catalyzed by CuO-NiO/?3-Al2O3

A simple method for N-alkylation of 1,2-diaminoethane with different alcohols in a fixed-bed reactor using cheap CuO-NiO/?3-Al2O3 as the catalyst has been developed. The present catalytic system was applicable in the N-alkylation of

METHOD FOR PRODUCING N-MONOALKYL-SUBSTITUTED ALKYLENE AMINE

PROBLEM TO BE SOLVED: To provide a method for producing an N-monoalkyl-substituted alkylene amine especially useful for uses such as medicine intermediates, agrochemical intermediates, urethane resin-foaming catalysts, surfactants and the like among alkyl-substituted alkylene amine compounds from an alcohol and an alkylene amine as raw materials. SOLUTION: This method for producing the N-monoalkyl-substituted alkylene amine is characterized by reacting the alkylene amine with a ≥2C alkyl alcohol in the presence of a copper-containing oxide catalyst system. The N-monoalkyl-substituted alkylenamine is produced in high conversion and in N-monoalkylation selectivity.

Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives

1-Arylalkyl-5-phenylsulfonamino-imidazole-4-carboxylic acid esters and their carboxamides with an additional secondary amino group were synthesized and identified as antiplatelet agents in a low micromolar range (Born-test, inducer collagen). To describe the mechanism of action more precisely the Born-test was carried out as well with ADP, adrenaline or PAF, respectively. In addition, two compounds were investigated for their COX-1 inhibitory activities. Provided the essential structural criteria are met i.e. amide group or ester, sulfonylamino rest, hydrophobic moieties, and a secondary amino function, slight structural modifications are able to shift the pattern of activity among the above platelet receptors. So, the ester 5c exhibits PAF antagonistic activity at IC 50 = 1 μM and COX-1 inhibition (IC50 = 0.4 μM). The carboxamide 6c shows ADP antagonistic properties (IC50 = 2 μM). Compound 6g is as well PAF antagonistic (IC50 = 4 μM) and a COX-1 inhibitor (IC50 = 1 μM). The derivative 6i shows a strong antiadrenergic (IC50 = 0.15 μM) and PAF antagonistic (IC 50 = 0.66 μM) effect.

PHARMACEUTICAL COMPOUNDS

Compounds of the formula: STR1 in which each R 1 is hydrogen, C 1-4 alkyl, C 1-4 alkoxy, halogen or nitro, and n is 0, 1, 2 or 3, R 2 is hydrogen, C 1-4 alkyl or C 2-4 alkenyl, R. sup.3 and R. sup.4 are each hydrogen, C 1-4 alkyl, optionally substituted phenyl or C. sub.6-9 cycloalkyl optionally substituted by 1 to 4 C 1-4 alkyl groups, R 5 is optionally substituted phenyl, tetrahydronaphthyl, phthalimido, saccharinyl, glutaramido, C 6-10 cycloalkyl optionally substituted with 1 to 4 C. sub.1-4 alkyl groups or a phenyl group, or C. sub.4-9 heterosubstituted cycloalkyl optionally substituted with 1 to 4 alkyl groups, x is 1, 2 or 3, y is 0 or 1 and z is 0, 1, 2 or 3; and salts thereof.The compounds are indicated for use in the treatment of disorders of the central nervous system.